Teva Pharma Industries Stock Probability Of Bankruptcy

TEVA Stock

USD 21.20 0.32 1.53%

Teva Pharma's odds of distress is under 36% at this time. It has slight probability of undergoing some form of financial crisis in the near future. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Teva balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Teva Pharma Piotroski F Score and Teva Pharma Altman Z Score analysis.

The current year's Market Cap is expected to grow to about 14.9 B. The current year's Enterprise Value is expected to grow to about 40.5 B

Teva Pharma Industries Company chance of distress Analysis

Teva Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Teva Pharma Probability Of Bankruptcy

Less than 36%

Most of Teva Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharma Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Teva Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Teva Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Teva Pharma Industries financial health.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.4

Earnings Share

(0.85)

Revenue Per Share

14.879

Quarterly Revenue Growth

0.125

Return On Assets

0.0556

The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Long Term Investments	Short Long Term Debt	Net Tangible Assets	Deferred Long Term Liab	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.71	0.73	0.27	0.93	0.83	0.85	0.71	0.92	0.13	-0.14	-0.67	0.78	-0.69	0.85	0.31	0.95	0.11	-0.33	-0.62	0.73	0.46	0.13	0.26	-0.15	-0.27
Total Stockholder Equity	0.71		0.1	0.82	0.79	0.29	0.8	0.47	0.56	0.62	-0.61	-0.57	0.13	-0.36	0.58	-0.28	0.64	0.52	0.05	0.02	0.56	-0.18	-0.51	0.61	-0.61	-0.41
Net Debt	0.73	0.1		-0.37	0.58	0.95	0.35	0.56	0.82	-0.48	0.36	-0.4	0.97	-0.58	0.59	0.66	0.81	-0.44	-0.45	-0.94	0.58	0.88	0.62	-0.18	0.32	0.01
Retained Earnings	0.27	0.82	-0.37		0.42	-0.26	0.42	0.19	0.17	0.66	-0.89	-0.12	-0.35	0.17	0.1	-0.58	0.17	0.52	0.47	0.45	0.32	-0.63	-0.88	0.83	-0.87	-0.54
Net Receivables	0.93	0.79	0.58	0.42		0.69	0.89	0.78	0.84	0.27	-0.29	-0.75	0.59	-0.61	0.85	0.3	0.84	0.12	-0.15	-0.4	0.58	0.22	-0.1	0.43	-0.3	-0.39
Total Liab	0.83	0.29	0.95	-0.26	0.69		0.56	0.6	0.85	-0.26	0.33	-0.6	0.95	-0.74	0.75	0.59	0.89	-0.23	-0.55	-0.89	0.6	0.85	0.58	-0.19	0.29	0.08
Total Current Assets	0.85	0.8	0.35	0.42	0.89	0.56		0.65	0.62	0.52	-0.21	-0.85	0.44	-0.71	0.9	0.14	0.69	0.37	-0.26	-0.19	0.38	0.08	-0.07	0.26	-0.2	-0.23
Short Term Debt	0.71	0.47	0.56	0.19	0.78	0.6	0.65		0.71	-0.1	-0.19	-0.58	0.51	-0.3	0.63	0.31	0.61	-0.14	0.08	-0.35	0.38	0.21	-0.01	0.24	-0.21	-0.27
Intangible Assets	0.92	0.56	0.82	0.17	0.84	0.85	0.62	0.71		-0.16	-0.16	-0.43	0.83	-0.49	0.66	0.43	0.93	-0.02	-0.24	-0.76	0.85	0.58	0.15	0.33	-0.19	-0.31
Accounts Payable	0.13	0.62	-0.48	0.66	0.27	-0.26	0.52	-0.1	-0.16		-0.45	-0.41	-0.39	-0.28	0.31	-0.43	-0.01	0.62	0.05	0.54	-0.09	-0.57	-0.56	0.37	-0.46	-0.18
Short Term Investments	-0.14	-0.61	0.36	-0.89	-0.29	0.33	-0.21	-0.19	-0.16	-0.45		-0.14	0.36	-0.37	0.08	0.47	-0.04	-0.41	-0.59	-0.38	-0.38	0.6	0.91	-0.86	0.95	0.57
Common Stock	-0.67	-0.57	-0.4	-0.12	-0.75	-0.6	-0.85	-0.58	-0.43	-0.41	-0.14		-0.41	0.79	-0.92	-0.21	-0.59	-0.07	0.34	0.18	-0.1	-0.2	-0.19	0.12	-0.12	-0.12
Long Term Debt	0.78	0.13	0.97	-0.35	0.59	0.95	0.44	0.51	0.83	-0.39	0.36	-0.41		-0.66	0.64	0.67	0.82	-0.31	-0.54	-0.94	0.6	0.87	0.63	-0.17	0.34	-0.02
Treasury Stock	-0.69	-0.36	-0.58	0.17	-0.61	-0.74	-0.71	-0.3	-0.49	-0.28	-0.37	0.79	-0.66		-0.85	-0.41	-0.67	-0.09	0.74	0.52	-0.25	-0.53	-0.48	0.27	-0.36	-0.08
Property Plant Equipment	0.85	0.58	0.59	0.1	0.85	0.75	0.9	0.63	0.66	0.31	0.08	-0.92	0.64	-0.85		0.37	0.76	0.06	-0.43	-0.43	0.36	0.38	0.26	-0.02	0.05	0.03
Current Deferred Revenue	0.31	-0.28	0.66	-0.58	0.3	0.59	0.14	0.31	0.43	-0.43	0.47	-0.21	0.67	-0.41	0.37		0.28	-0.37	-0.42	-0.64	0.06	0.61	0.59	-0.17	0.42	0.04
Good Will	0.95	0.64	0.81	0.17	0.84	0.89	0.69	0.61	0.93	-0.01	-0.04	-0.59	0.82	-0.67	0.76	0.28		0.0	-0.38	-0.74	0.8	0.62	0.23	0.15	-0.06	-0.16
Long Term Investments	0.11	0.52	-0.44	0.52	0.12	-0.23	0.37	-0.14	-0.02	0.62	-0.41	-0.07	-0.31	-0.09	0.06	-0.37	0.0		-0.09	0.33	0.14	-0.39	-0.45	0.35	-0.39	-0.21
Short Long Term Debt	-0.33	0.05	-0.45	0.47	-0.15	-0.55	-0.26	0.08	-0.24	0.05	-0.59	0.34	-0.54	0.74	-0.43	-0.42	-0.38	-0.09		0.56	-0.16	-0.64	-0.67	0.5	-0.57	-0.31
Net Tangible Assets	-0.62	0.02	-0.94	0.45	-0.4	-0.89	-0.19	-0.35	-0.76	0.54	-0.38	0.18	-0.94	0.52	-0.43	-0.64	-0.74	0.33	0.56		-0.65	-0.95	-0.67	0.22	-0.34	-0.07
Deferred Long Term Liab	0.73	0.56	0.58	0.32	0.58	0.6	0.38	0.38	0.85	-0.09	-0.38	-0.1	0.6	-0.25	0.36	0.06	0.8	0.14	-0.16	-0.65		0.47	-0.05	0.41	-0.39	-0.27
Long Term Debt Total	0.46	-0.18	0.88	-0.63	0.22	0.85	0.08	0.21	0.58	-0.57	0.6	-0.2	0.87	-0.53	0.38	0.61	0.62	-0.39	-0.64	-0.95	0.47		0.84	-0.49	0.55	0.35
Capital Surpluse	0.13	-0.51	0.62	-0.88	-0.1	0.58	-0.07	-0.01	0.15	-0.56	0.91	-0.19	0.63	-0.48	0.26	0.59	0.23	-0.45	-0.67	-0.67	-0.05	0.84		-0.82	0.87	0.6
Net Invested Capital	0.26	0.61	-0.18	0.83	0.43	-0.19	0.26	0.24	0.33	0.37	-0.86	0.12	-0.17	0.27	-0.02	-0.17	0.15	0.35	0.5	0.22	0.41	-0.49	-0.82		-0.89	-0.76
Net Working Capital	-0.15	-0.61	0.32	-0.87	-0.3	0.29	-0.2	-0.21	-0.19	-0.46	0.95	-0.12	0.34	-0.36	0.05	0.42	-0.06	-0.39	-0.57	-0.34	-0.39	0.55	0.87	-0.89		0.49
Capital Stock	-0.27	-0.41	0.01	-0.54	-0.39	0.08	-0.23	-0.27	-0.31	-0.18	0.57	-0.12	-0.02	-0.08	0.03	0.04	-0.16	-0.21	-0.31	-0.07	-0.27	0.35	0.6	-0.76	0.49

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	(0.0174)	(0.0788)	0.008748	(0.0535)	(0.0129)	(0.0122)
Asset Turnover	0.32	0.31	0.29	0.33	0.34	0.63
Gross Profit Margin	0.48	0.44	0.45	0.46	0.47	0.38
Net Debt	25.4B	24.2B	21.3B	18.8B	16.9B	17.8B
Total Current Liabilities	13.7B	13.2B	11.0B	11.5B	12.2B	6.5B
Non Current Liabilities Total	28.7B	26.4B	25.4B	23.8B	23.1B	24.3B
Total Assets	57.5B	50.6B	47.7B	44.0B	43.5B	26.4B
Total Current Assets	13.5B	13.0B	12.6B	12.1B	12.5B	7.7B
Total Cash From Operating Activities	538M	1.2B	798M	1.6B	1.4B	2.0B

	Return On Equity	-0.18
	Return On Asset	0.0556
	Profit Margin	(0.06) %
	Operating Margin	0.23 %
	Current Valuation	38.37 B
	Shares Outstanding	1.13 B
	Shares Owned By Institutions	57.83 %
	Number Of Shares Shorted	22.41 M
	Price To Earning	15.67 X
	Price To Book	3.90 X
	Price To Sales	1.41 X
	Revenue	15.85 B
	Gross Profit	6.97 B
	EBITDA	433 M
	Net Income	(615 M)
	Cash And Equivalents	2.22 B
	Cash Per Share	2.00 X
	Total Debt	20.15 B
	Debt To Equity	2.27 %
	Current Ratio	0.99 X
	Book Value Per Share	5.35 X
	Cash Flow From Operations	1.37 B
	Short Ratio	2.73 X
	Earnings Per Share	(0.85) X
	Price To Earnings To Growth	1.29 X
	Target Price	22.7
	Number Of Employees	37 K
	Beta	0.87
	Market Capitalization	23.66 B
	Total Asset	43.48 B
	Retained Earnings	(13.53 B)
	Working Capital	238 M
	Current Asset	18.4 B
	Current Liabilities	13.01 B
	Five Year Return	2.95 %
	Net Asset	43.48 B

Teva Pharma Industries Stock Probability Of Bankruptcy

Teva Pharma Industries Company chance of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Teva Pharma Probability Of Bankruptcy

Teva Probability Of Bankruptcy Driver Correlations

Teva Probability Of Bankruptcy Peer Comparison

Teva Pharma Main Bankruptcy Drivers

Teva Pharma ESG Sustainability

Teva Fundamentals

About Teva Pharma Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY